Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk CEO to step down after eight years at the helm
Novo Nordisk (NYSE:NVO) CEO Lars Fruergaard Jørgensen is stepping down after eight years leading the Danish pharmaceutical giant, known for its blockbuster obesity and diabetes drugs Wegovy and Ozempic. The company said on Friday the decision was made by mutual agreement with the company's board amid recent market challenges, including increased competition and a significant decline in the company's share price since mid-2024.
Novo Nordisk CEO to step down amid pressure from obesity drug competition
Novo Nordisk (NYSE:NVO) has announced that chief executive Lars Fruergaard Jørgensen will step down after eight years in the role, as the company contends with growing pressure in the obesity treatment market. The Danish pharmaceutical group, best known for its Wegovy weight-loss drug, said Jørgensen would stay on temporarily to support a smooth leadership transition.
Ozempic maker Novo Nordisk boots CEO over stock-price fall
Lars Fruergaard Jorgensen, the chief executive of once-highflying Danish drugmaker Novo Nordisk, is stepping down after eight years in the role, the maker of Ozempic and Wegovy drugs announced on Friday.
Novo Nordisk CEO to Step Down Amid Market Challenges
Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to support a smooth transition to new leadership.
Novo Nordisk's CEO to step down as competition weighs on Wegovy maker's share price
The Danish pharmaceutical giant said Fruergaard Jørgensen would remain in his post "for a period to support a smooth transition to new leadership."
ETFs to Capitalize on the Novo Nordisk-Septerna Deal
Novo Nordisk announces a $2.2 billion deal with Septerna to tap the growing obesity treatment market.
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Is It Time to Buy the Dip in Novo Nordisk Stock?
Despite a double beat in its quarterly earnings on May 7, Novo Nordisk A/S NYSE: NVO stock is still down nearly 50% in 2025. However, the stock is now trading near its 52-week low and is a discount to itself in several metrics.
Ignore The Noise - Novo Nordisk Is A Clear Buy
Novo Nordisk's stock has declined 55% from its all-time high, but the company continues to report strong quarterly results with significant revenue and profit growth. Despite slowing growth rates and revised guidance, NVO's rich pipeline and strategic acquisitions position it for sustained high growth, particularly in diabetes, GLP-1, and obesity care. The company's current product portfolio is well-protected by patents until at least 2030, ensuring stable revenue from key products like Wegovy and Ozempic.
Septerna stock pops on partnership with Novo Nordisk to develop obesity therapies
Septerna (NASDAQ:SEPN) shares surged almost 50% after the announcement of an exclusive global collaboration and license deal with Novo Nordisk (NYSE:NVO) to develop oral small molecule medicines targeting obesity and other cardiometabolic diseases. The partnership brings together Septerna's expertise in G protein-coupled receptor (GPCR) drug discovery with Nono Nordisk's established obesity and metabolic disease therapies, which include the injectables Wegovy and Ozempic.
Novo Nordisk: A Strategy With High Potential For Volatile Times
Novo Nordisk has a strong economic moat based on significant market shares in diabetes and obesity care, and promising pipeline drugs, though facing competition and political pressures. The company shows very high profitability and about 20% EPS and dividend growth. My Fair Value estimate, derived from three distinct sources, is $83, suggesting about 27% potential upside.
Novo Nordisk: Is obesity wonder drug Wegovy losing its investment appeal?
Private investors considering Novo Nordisk (NYSE:NVO) should approach with measured optimism. The Danish drugmaker is a global leader in the fast-growing obesity market, but Morgan Stanley believes the near-term outlook is mixed.
